

FarmaForce Limited
Level 9, 85 Castlereagh St
Sydney, NSW 2000

25th June 2018

ASX ANNOUNCEMENT

FARMAFORCE INCREASES BUSINESS ACTIVITY AND REVENUE GROWTH

The executive management of FarmaForce Limited (ASX:FFC) is excited to announce new significant business wins leading to a noteworthy forecasted sales increase.


FarmaForce General Manager, Harry Simeonidis said, "This is an exciting time for the company, shareholders, and the Farmaforce employees. By securing new top tier client partnerships we continue to increase revenue and market share." He continued, "Since FY14/15, our revenues have increased significantly year on year and we are expecting this trend to continue well into FY18/19. Based on our current forecast we foresee an average annual growth rate (AAGR) of 155% over the five years since 2014 to 2019."

It is estimated that current contracts will translate to a projected revenue forecast of over \$10m by FY18/19 even before considering the value of any additional contracts.

"With our continued investment in people, processes and digital tools, we have seen a considerable improvement in operational efficiencies that have resulted in our ability to positively drive new business opportunities to conversion. This considerable improvement in performance is also a reflection of the long-term strategy of FarmaForce coming to fruition as we begin to capitalise on the ever-changing dynamics of the pharmaceutical industry," Mr Simeonidis concluded.



Realised Revenue + Forecast



For additional information, please contact;

Investor Relations

Investor.relations@farmaforce.com.au

02 8239 5400

About FarmaForce

Shaping the future, together

FarmaForce is a contract sales organisation offering innovative sales solutions to the Australian pharmaceutical industry.

Farmaforce.com.au